Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement - A randomized, double-blind, placebo-controlled trial

被引:120
作者
Heit, JA
Elliott, CG
Trowbridge, AA
Morrey, BF
Gent, M
Hirsh, J
机构
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Univ Utah, Latter Day St Hosp, Sch Med, Salt Lake City, UT 84143 USA
[3] Texas A&M Univ, Coll Med, Temple, TX 76508 USA
[4] McMaster Univ, Hamilton, ON, Canada
关键词
heparin; low-molecular-weight; thromboembolism; venous thrombosis; arthroplasty; replacement; knee; hip;
D O I
10.7326/0003-4819-132-11-200006060-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The optimal duration of prophylaxis against venous thromboembolism after total hip or knee replacement is uncertain. Objective: To determine the efficacy and safety of extended out-of-hospital prophylaxis with low-molecular-weight heparin (ardeparin sodium). Design: Randomized, double-blind, placebo-controlled trial. Setting: 33 community, university, or university-affiliated hospitals. Patients: 1195 adults who had elective total hip or knee replacement and completed 4 to 10 days of postoperative ardeparin prophylaxis. Intervention: Daily subcutaneous ardeparin (100 anti-X-a IU/kg of body weight) or placebo from time of hospital discharge to 6 weeks after surgery. Measurements: Symptomatic, objectively documented venous thromboembolism or death, along with major bleeding, from time of hospital discharge to 12 weeks after surgery. Results: Patients who received ardeparin (n = 607) and those who received placebo (n = 588) did not differ significantly in the cumulative incidence of venous thromboembolism or death (9 cases [1.5%] compared with 12 cases [2.0%]; odds ratio, 0.7 [95% Cl, 0.3 to 1.7]; P > 0.2; absolute difference, -0.56 percentage points [Cl, -2.2 to 1.1 percentage points]) or major bleeding (2 cases [0.3%] compared with 3 cases [0.5%]). Conclusions: Among patients who had total knee or total hip replacement and received 4 to 10 days of postoperative ardeparin prophylaxis, the cumulative incidence of symptomatic venous thromboembolism or death after hospital discharge was not significantly reduced by extended out-of-hospital ardeparin prophylaxis. Extended ardeparin use could provide a maximum 2.2-percentage point true reduction in such events. The benefit of extended ardeparin use is not clinically important for patients. Future research should identify high-risk patients who would benefit most from extended prophylaxis.
引用
收藏
页码:853 / +
页数:10
相关论文
共 16 条
[1]   Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement [J].
Bergqvist, D ;
Benoni, G ;
Bjorgell, O ;
Fredin, H ;
Hedlundh, U ;
Nicolas, S ;
Nilsson, P ;
Nylander, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :696-700
[2]   Prevention of venous thromboembolism [J].
Clagett, GP ;
Anderson, FA ;
Geerts, W ;
Heit, JA ;
Knudson, M ;
Lieberman, JR ;
Merli, GJ ;
Wheeler, HB .
CHEST, 1998, 114 (05) :531S-560S
[3]   SOME METHODS FOR STRENGTHENING THE COMMON X2 TESTS [J].
COCHRAN, WG .
BIOMETRICS, 1954, 10 (04) :417-451
[4]  
Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26
[5]  
FRANCIS CW, 1986, CLIN ORTHOP RELAT R, V232, P271
[6]  
FRIEDMAN RJ, 1994, J BONE JOINT SURG AM, V76A, P1174
[7]   Postthrombotic syndrome after hip or knee arthroplasty - A cross-sectional study [J].
Ginsberg, JS ;
Gent, M ;
Turkstra, F ;
Buller, HR ;
MacKinnon, B ;
Magier, D ;
Hirsh, J .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (05) :669-672
[8]  
Heit JA, 1997, THROMB HAEMOSTASIS, V77, P32
[9]   Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish prolonged prophylaxis (DaPP) study [J].
Lassen, MR ;
Borris, LC ;
Anderson, BS ;
Jensen, HP ;
Bro, HPS ;
Andersen, G ;
Petersen, AO ;
Siem, P ;
Horlyck, E ;
Jensen, BV ;
Thomsen, PB ;
Hansen, BR ;
Erin-Madsen, J ;
Moller, JC ;
Rotwitt, L ;
Christensen, F ;
Nielsen, JB ;
Jorgensen, PS ;
Paaske, B ;
Torholm, C ;
Hvidt, P ;
Jensen, NK ;
Nielsen, AB ;
Appelquist, E ;
Hansen, OG ;
Mortensen, D ;
Tjalve, E .
THROMBOSIS RESEARCH, 1998, 89 (06) :281-287
[10]   The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin -: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty [J].
Leclerc, JR ;
Gent, M ;
Hirsh, J ;
Geerts, WH ;
Ginsberg, JS .
ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (08) :873-878